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Abstract: The reported compound 4 was synthesized and fully characterized by 1H NMR, 
13C NMR, 11B NMR, 19F NMR, and high resolution mass spectrometry. 
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Of the boron-containing compounds that are currently in pharmaceutical development programs, 
boronic acids [1,2], boronate esters [3,4], benzoxaboroles [5,6], and oxazaborolidines [7,8] are 
frequently used boron functional groups. Having an empty p-orbital on the trivalent boron atom, these 
analogs interact with their targets to form tetrahedral intermediates. Organotrifluoroborates, on the 
other hand, are seldom considered in biological applications due to their lack of an empty p-orbital. 
Srebnik and coworkers, the first group to investigate the biological activity of a series of aryl 
organotrifluoroborates in enzyme-inhibition assays, reported that aryl potassium trifluoroborates were 
much more potent than the corresponding boronic acids against α-chymotrypsin and trypsin [9,10]. 
The toxicological profile of organotrifluoroborates were also investigated by Oliveira and co-workers, 
who showed that thiophene-3-trifluoroborate exhibits minimal toxicity in a mouse model, and 
concluded that this class of compounds is suitable for further development as pharmacologically active 
agents [11]. Despite their promising biological studies, the reported studies of organotrifluoroborates 
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have focused mainly on simple aryl/heteroaryl structures. Herein, we report the synthesis of the 
dipeptidyl organotrifluroborate, which should possess additional hydrophilic elements and 
hydrophobic moieties, which are vital factors for ligand/receptor binding. 
Result and Discussion 
The desired product was prepared as follows. H-L-valine-methyl ester (1) was first coupled with 
Boc-L-phenylalanine-OH (2) by general peptide coupling protocol [12] followed by removal of  
t-butyloxycarbonyl (Boc) protecting group to afford dipeptide 3 (Scheme 1). Then, compound 3 was 
condensed with potassium 4-formylphenyltrifluoroborate to give the corresponding imine 
intermediate. Finally, the resulting intermediate was directly reduced by 5-ethyl-2-methylpyridine 
borane complex (PEMB) [13] to give the final product 4 in 64% yield.  
Scheme 1. (a) TBTU (1.3 equiv), DIPEA (4.0 equiv), CH2Cl2 (0.1 M); (b) TFA (20%), 
CH2Cl2 (0.1 M); (c) 4-formylphenyltrifluoroborate (1.0 equiv), PEMB (0.5 equiv), MeOH 
(0.5 M). 
 
Experimental  
To a vial containing potassium 4-formylphenyltrifluoroborate (118 mg, 0.55 mmol) in MeOH was 
added 3 (411 mg, 0.83 mmol) to generate a 0.5 M solution. The reaction mixture was stirred for 3 h at 
room temperature. PEMB (0.042 mL, 0.28 mmol) was then added, and stirring was continued for 5 h. 
The solvent was then removed in vacuo, and the resulting crude material was washed with hexane. The 
crude solid was purified by continuous Soxhlet extraction (3 h) with acetone. The collected solvent 
was concentrated and then precipitated with acetone/ hexane to afford the desired pure product 4 as a 
white solid (167 mg, 64% yield). 1H NMR (300 MHz, CD3OD) δ 7.58 (d, J = 7.8 Hz, 2H), 7.36–7.29 
(m, 3H), 7.28–7.18 (m, 2H), 4.34 (d, J = 9.9 Hz, 1H), 4.11–3.97 (m, 3H), 3.68 (s, 3H), 3.14 (d, J = 7.2 Hz, 
2H), 2.09 (oct, J = 6.6 Hz, 1H), 0.95 (dd, J = 6.6, 3.9 Hz, 6H). 13C NMR (75.5 MHz, CD3OD) δ 172.4, 
168.8, 135.2, 133.6, 130.7, 130.1, 129.5, 128.9, 128.8, 61.4, 59.7, 52.7, 51.8, 37.9, 32.1, 19.5, 18.8.  
11B NMR (192.5 MHz, acetone-d6) δ 4.0. 19F NMR (564.6 MHz, CD3OD) δ 144.8. M.p. 207 °C. 
HRMS (ESI, negative ion) m/z calcd for [M-K]− = 435.2069, m/z found 435.2088. 
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